Clinical efficacy of arsenic trioxide combined with VAD in the treatment of refractory and relapsed multiple myeloma / 中国综合临床

ABSTRACT

Objective To investigate the efficacy of arsenic trioxide combined with VAD in the treatment of refractory relapsed multiple myeloma.Methods The clinical data of sixty-five patients with recurrent MM treated in Guigang City People's Hospital during the past 5 years was retrospectively analyzed.The patients were randomly divided into the experimental group(33 cases)and the control group(32 cases).The experimental group was treated with arsenic trioxide combined with VAD,and the control group adopted with VAD treatment program.After 4 courses of treatment,the signs and symptoms of the two groups were detected and observed.Results The total effective rate of the experimental group was 72.7%(24/33),which was obviously better than that of the control group,with the total effective rate was 53.1%(17/32).The difference was statistically significant(P=0.0364).The detection indexes of the experimental group were better than those of the control group,about 20%.Conclusion Arsenic trioxide combined with VAD is effective and efficient in the treatment of multiple myeloma.It is an effective way to relieve MM in the current MM treatment program.